Loading…
Loading grant details…
| Funder | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES |
|---|---|
| Recipient Organization | Brigham Young University |
| Country | United States |
| Start Date | Jan 13, 2022 |
| End Date | Dec 31, 2025 |
| Duration | 1,448 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10439133 |
Abstract/Project Summary Extraintestinal Escherichia coli (ExPEC) are bacteria that live in the intestines of mammals and cause life- threatening illnesses when they infect other tissues. The societal burden due to this group of pathogens is vast and growing, in part because of increasing antibiotic resistance and a lack of vaccination options. Urosepsis,
pneumonia and neonatal meningitis are human diseases caused by these strains. Our long-term goal is to understand the molecular mechanisms of pathogenesis of ExPEC that circulate in animals and humans. Many animals are susceptible to these pathogens and represent reservoirs for human infection. The central
hypothesis of this application, based on substantial preliminary data, is that some mastitis strains of bovine origin also have the potential to cause disease in multiple hosts including humans. This is a novel finding, based on evidence that includes genetic similarities with human ExPEC lineages, virulence in Galleria
mellonella infections, resistance to human serum, and the ability to cause sepsis and urinary tract infections in mice. The objective of this work is to characterize virulence factors that allow some mastitis-associated strains to infect multiple hosts and cause extraintestinal disease. A genome-wide screen for mastitis strain M12
virulence factors led to the discovery of a cluster of capsule biosynthesis genes encoding a Group 3 capsule. Group 3 capsules are present in many ExPEC strains, but their roles are not well defined. An unencapsulated mutant strain was unable to infect spleens or kidneys of mice. Additional mastitis-associated strains in our
collection also encode Group 3 capsules, which may promote virulence by helping these bacteria avoid neutrophil phagocytosis. Neutrophils are critically important for defense against many bacterial pathogens including ExPEC, but we do not fully comprehend the mechanisms whereby ExPEC resist being engulfed or
killed by these cells. The objectives of this proposal will be accomplished with three specific aims: (1) Estimate the fraction of mastitis-associated E. coli that can cause disease in established models of human ExPEC infection. We will utilize novel DNA barcoding strategies to measure competitive fitness of multiple
strains in these experiments. (2) Characterize the role of Group 3 capsules found in mastitis-associated strains in conditions relevant to human disease. We will test whether these capsules promote resistance to killing by neutrophils or serum and during experimental infections. (3) Identify all of the genes that are needed for
production of the M12 Group 3 capsule, including those both inside and outside the capsule locus. Since building the capsule is a critical virulence function, this could identify targets for new therapies. This proposal is innovative because it is based on the novel concept that mastitis-associated strains are potential human
pathogens. It is significant because it will provide greater understanding of the molecular basis for ExPEC virulence in multiple hosts, and the relationships between ExPEC found in different environments. These findings may inform new ways to prevent disease caused by these bacteria and improve public health.
Brigham Young University
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant